Testing Across the
Continuum of Cancer
A comprehensive portfolio of liquid and tissue precision oncology tests for patients diagnosed with early or advanced-stage cancer.
A Fast CGP Panel with Guideline-Recommended Actionable Biomarkers
Our Guardant360 CDx test is our FDA-approved liquid biopsy that provides results in less than 7 days to inform treatment decisions.1 Guardant360 CDx has broad commercial and Medicare coverage for all advanced solid tumors.2
Liquid Comprehensive Genomic Profiling with an Expanded Panel of Biomarkers
The Guardant360 liquid biopsy test helps find additional treatment options with an expanded panel of biomarkers, including all guideline-recommended biomarkers across advanced solid tumors. Guardant360 has broad commercial and Medicare coverage for all advanced solid tumors.
The only tissue comprehensive genomic profiling with AI-powered PD-L1 detection
Our Guardant360 TissueNext tissue biopsy test finds actionable information when tissue testing is appropriate. The test leverages our AI-powered scoring algorithm to improve PD-L1 detection by >20% in NSCLC.1,2 * Guardant360 TissueNext has broad commercial and Medicare coverage for advanced solid tumors.
- Guardant360 TissueNext Assay Specifications. Guardant Health Inc. Redwood City, CA.
- Data on file. Guardant Health, Inc. Redwood City, CA.
Minimal Residual Disease Detection and Recurrence Monitoring
Guardant Reveal is a completely tissue-free test that detects circulating tumor DNA (ctDNA) for minimal residual disease (MRD) assessment in early-stage colorectal, breast, and lung cancers. In addition to detection of MRD, Guardant Reveal is also available to monitor recurrence in previously diagnosed patients.16
The Only Tissue-Free Biopsy to Measure Treatment Response
Our Guardant360 Response test is the first tissue-free biopsy that enables doctors to view molecular response, or changes in circulating tumor DNA (ctDNA) levels, to get an early indication of patient response to immunotherapy or targeted therapy for advanced stage solid tumors.17 Studies show the Guardant360 Response test can predict treatment response 8 weeks earlier than current standard-of-care imaging.4-13